Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryFeb212016	Fate Therapeutics to Present Preclinical Data for ProTmune™ at 2016 BMT Tandem Meetings Poster Presentation to Highlight Anti-Tumor Properties of Ex Vivo Programmed Donor T Cells Phase 1/2 Clinical Trial of ProTmune in Mobilized Peripheral Blood HCT to Commence Enrollment in Mid-2016 SAN DIEGO, Feb. 21, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML Fate Therapeutics to Present Preclinical Data for ProTmune™ at 2016 BMT Tandem Meetings 17.1 KB
Toggle SummaryNov052015	Fate Therapeutics to Present Strategy for the Development of Off-the-Shelf Cancer Immunotherapies at ASH 2015 Proprietary Pluripotent Cell Platform for Engineered Adoptive Immunotherapies to be Highlighted During Two Poster Sessions Read All »	View HTML Fate Therapeutics to Present Strategy for the Development of Off-the-Shelf Cancer Immunotherapies at ASH 2015 61.9 KB
Toggle SummaryMay062014	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2014 Financial Results on May 13, 2014 SAN DIEGO, May 6, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2014 Financial Results on May 13, 2014 10.4 KB
Toggle SummaryMay042015	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2015 Financial Results on May 7, 2015 SAN DIEGO, May 4, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that the Company will host a conference call and live Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2015 Financial Results on May 7, 2015 10.8 KB
Toggle SummaryMay022016	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2016 Financial Results on May 9, 2016 SAN DIEGO, May 02, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2016 Financial Results on May 9, 2016 11.7 KB
Toggle SummaryMay082017	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2017 Financial Results SAN DIEGO, May 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2017 Financial Results 11.9 KB
Toggle SummaryMay032018	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2018 Financial Results SAN DIEGO , May 03, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All »	View HTML
Toggle SummaryApr302019	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2019 Financial Results SAN DIEGO , April 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and Read All »	View HTML
Toggle SummaryMay042020	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2020 Financial Results SAN DIEGO , May 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All »	View HTML
Toggle SummaryApr292021	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2021 Financial Results SAN DIEGO , April 29, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will host a Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.